We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IntriCon Corp (IIN) USD1

Sell:$13.70 Buy:$13.90 Change: $1.46 (9.63%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $1.46 (9.63%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $1.46 (9.63%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Intricon Corporation is a joint development manufacturer (JDM) of micromedical components, sub-assemblies and final devices. The Company serves as a JDM partner to medical device original equipment manufacturers (OEMs) by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. The Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and body-worn devices for medical device manufacturers. It offers medical device manufacturers the capabilities to design, develop, manufacture, package and distribute medical devices. The Company has facilities in facilities in Minnesota, Illinois, California, Singapore, Indonesia and Germany.

Contact details

1260 Red Fox Road
United States
+1 (651) 6369770

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$138.61 million
Shares in issue:
9.14 million
Health Care Equipment
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Scott Longval
    President, Chief Executive Officer, Director
  • Annalee Lutgen
    Interim Chief Financial Officer, Finance Director, Treasurer
  • Michael Geraci
    Senior Vice President - Sales and Marketing
  • Dennis Gonsior
    Senior Vice President, Global Operations
  • David Liebl
    Vice President - Research & Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.